Bi-Specific T-cell Engager

  • (L to R): Mr. Charlie Naranjo, Dr. Brian Choi, Mr. Tony Goitia

  • ajax-loader

  • Dr. Brian Choi signs MBTC Research Grant Agreement

  • (L to R): Dr. Brian Choi, Dr. John Sampson, Mr. Tony Goitia and Mr. Charlie

  • Dr. John Sampson, of Duke University and MBTC Founder Mr. Tony Goitia discuss research goals

  • MBTC Founders and Duke University Researchers exchanging ideas

“Glioblastoma is a lethal type of brain tumor with few treatment options.  At the Preston Robert Tisch Brain Tumor Center at Duke, we have developed a novel approach that harnesses the body’s own immune system to combat this deadly cancer.  One of our most exciting experimental therapies, the Bi-specific T-cell Engager (BiTE) has the ability to eradicate tumors, without risking damage to normal, healthy brain tissue.  We are incredibly fortunate to receive financial support from the MBTC.  This timely contribution from the MBTC will be critical as we prepare clinical trials to test this new treatment, with hopes that it will eventually provide a solution for patients diagnosed with this devastating illness.” ~ Brian Choi, Researcher

Please remember that because MBTC is a small organization, we have almost no overhead and very little administrative costs.  That means that you can be sure that your contribution will go almost entirely in support this project and our other worthy goals.